Abstract: Provided is a method for the use of a bradykinin B1 receptor antagonist of formula I: X-CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-?(Me)Phe-Ser-D-?Nal-Aaa8-OH (I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1 or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0 is Lys, Orn or Cit; Aaa1 is Arg or Cit, and preferably Arg; Aaa2 is Oic, Hyp or Pro, and preferably Oic; Aaa3 is Pro or Oic, and preferably Pro; and Aaa8 is Ile, Leu or Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of the compound to a patient in need of such treatment. Also provided are compositions containing such antagonists and their thereof.
Type:
Grant
Filed:
June 12, 2006
Date of Patent:
April 26, 2011
Assignee:
Societe de Commercialisation des Produits de la Recherche Applique Socpra Sciences Sante et Humaines S.E.C.
Inventors:
François Nantel, Roger Chammas, Pierre Sirois, Bruno Joseph Battistini